# Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

> **NCT01802320** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 18 (actual)

## Conditions studied

- Colon Mucinous Adenocarcinoma
- Colon Signet Ring Cell Adenocarcinoma
- Rectal Mucinous Adenocarcinoma
- Rectal Signet Ring Cell Adenocarcinoma
- Recurrent Colon Carcinoma
- Recurrent Rectal Carcinoma
- Stage IIIA Colon Cancer
- Stage IIIA Rectal Cancer
- Stage IIIB Colon Cancer
- Stage IIIB Rectal Cancer
- Stage IIIC Colon Cancer
- Stage IIIC Rectal Cancer
- Stage IVA Colon Cancer
- Stage IVA Rectal Cancer
- Stage IVB Colon Cancer
- Stage IVB Rectal Cancer

## Interventions

- **DRUG:** Akt Inhibitor MK2206
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT01802320
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2015-06
- **Final completion:** 2015-08-05
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2019-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01802320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01802320, "Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01802320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*